查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830833

2025年性行為感染傳染病分子診斷全球市場報告

Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，性行為感染感染分子診斷市場規模迅速擴張，從2024年的33.1億美元成長至2025年的36.7億美元，複合年成長率達10.9%。這段歷史時期的成長可歸因於性行為感染盛行率的上升、核酸增幅檢查應用的增加、政府篩檢措施帶來的認知度的提升、全球衛生組織的支持以及診斷實驗室的早期應用。

預計未來幾年性行為感染分子診斷市場將快速成長，到2029年將達到54.8億美元，複合年成長率為10.5%。預測期內的成長可歸因於對早期疾病檢測的日益重視、對個性化診斷的需求不斷成長、性行為感染舉措的不斷擴展、公私合營的不斷加強以及對非侵入性檢測方法的日益偏好。這段時期的主要趨勢包括分子檢測技術的進步、照護現場診斷設備的創新、基於多重PCR的檢測組合的開發、攜帶式和自動化系統的進步，以及用於結果解讀的人工智慧的整合。

性行為感染傳染病 (STD) 的分子診斷技術透過檢測傳染源的遺傳物質（DNA或RNA）來確認其存在。這些技術高度準確且靈敏，即使在無症狀病例中也能檢測到。透過分析病原體的分子結構，這些診斷方法能夠進行明確鑑定，從而支持更快、更準確的診斷。

性傳染病分子診斷的主要產品類型包括儀器和服務、耗材和軟體。儀器包括用於病原體檢測的診斷設備和平台，而服務則涵蓋由醫療保健或診斷公司提供的實驗室檢測、樣本處理和診斷結果解讀。這些診斷技術採用多種技術，包括披衣菌感染檢測和即時檢測，用於各種應用，包括沙眼衣原體 (CT)、淋病奈瑟菌 (NG)、梅毒、淋病、單純皰疹病毒 (HSV)、人類乳突病毒 (HPV)、人類免疫力缺乏病毒 (HIV)、滴蟲、解脲支原體和黴漿菌的檢測。

美國關稅的快速上漲以及隨之而來的2025年春季貿易摩擦，對醫療設備行業產生了重大影響，尤其對進口診斷影像設備零件、手術用不銹鋼和塑膠耗材的影響。醫院和診所抵制漲價，擠壓了製造商的淨利率。監管障礙加劇了這個問題，因為與關稅相關的供應商變更通常需要設備重新認證，從而延緩了產品上市時間。企業正在透過雙重採購關鍵零件、擴大國內商品化生產以及加快具成本效益材料的研發來降低風險。

本研究報告是商業研究公司（The Business Research Company）新報告系列的一部分，該系列提供性行為感染傳染病分子診斷的市場統計數據，包括全球市場規模、各地區市場佔有率、性行為感染傳染性行為感染分子診斷市場佔有率的競爭對手，以及詳細的性行為感染感染分子診斷細分市場、市場趨勢和商業機會，為您提供在性行為感染傳播感染分子診斷行業取得成功所需的數據。這份性行為感染分子診斷市場研究報告透過對產業現狀和未來情勢的詳細分析，為您提供全面的展望。

性行為感染感染 (STI) 盛行率的上升預計將推動性行為感染感染 (STI) 分子診斷市場的成長。 STI 是由細菌、病毒或寄生蟲引起的感染疾病，透過性接觸傳播，影響生殖系統和泌尿器官系統。盛行率的上升主要是由於防護措施的使用不一致，這促進了性活躍人群之間的傳播。分子診斷能夠早期且準確地檢測出病原體，包括無症狀病例，從而及時治療，遏制疾病傳播，改善患者預後。例如，根據美國非營利組織 NACCHO（全國縣市衛生官員協會）的數據，2024 年 1 月總合報告了 3,755 例先天性梅毒病例，比 2021 年到 2022 年增加了 31%。這種日益成長的盛行率正在推動性傳染感染分子診斷市場的發展。

為了提高診斷的速度、準確性和可及性，該市場的主要企業正專注於快速即時聚合酵素鏈鎖反應(PCR) 設備等創新。這些可攜式設備將樣品製備、擴增和檢測集於一身，能夠在傳統實驗室外進行高靈敏度的病原體檢測。例如，2025 年 3 月，美國診斷科技公司 Visby Medical 推出了 Visby Medical 女性性健康檢驗。這種一次性手持式 PCR 設備無需外部設備或低溫運輸物流，即可在 30 分鐘內從陰道樣本中識別出披衣菌感染、淋病和滴蟲。該測試獲準憑處方箋在家中使用，是第一個獲得 FDA 批准的可在臨床環境之外使用的多種性傳播感染的分子診斷測試，反映了分散化和可及性測試的趨勢。

2024年12月，總部位於美國的照護現場和家用診斷解決方案提供商OraSure Technologies收購了Sherlock Biosciences。此次收購整合了Sherlock市售的披衣菌感染和淋病自檢產品，擴大了OraSure在性健康領域的分子診斷產品組合。 Sherlock Biosciences專注於性行為感染傳染病的分子診斷。

性行為感染分子診斷市場由提供檢測開發、樣本收集、核酸擴增和即時診斷等服務的供應商所獲得的收益所構成。市場價值還包括服務提供者銷售的或包含在其服務產品中的相關產品的價值。性行為感染分子診斷市場還包括聚合酵素鏈鎖反應套件、恒溫核酸增幅套件、基於成簇規律間隔短回文重複序列的檢測以及無需儀器的分子診斷系統的銷售。該市場的價值鏈是「工廠門口」價值，即產品製造商或創造者向其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接向最終客戶銷售的產品價值。該市場中的產品價值還包括產品創造者銷售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球性行為感染傳染病分子診斷：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球性行為感染傳染病分子診斷市場：成長率分析
  • 全球性行為感染傳染病分子診斷市場表現：規模與成長，2019-2024
  • 全球性行為感染傳染病分子診斷市場預測：規模與成長，2024-2029年，2034年
  • 全球性行為感染傳染病分子診斷：總目標市場（TAM）

第6章 市場細分

  • 全球性行為感染傳染病分子診斷市場：依產品、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 設備和服務
  • 耗材
  • 軟體
  • 全球性行為感染傳染病分子診斷市場：依技術、績效與預測，2019-2024 年、2024-2029 年、2034 年
  • 實驗室檢查
  • 就地檢驗
  • 全球性行為感染傳染病分子診斷市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 披衣菌感染披衣菌 (CT) 或淋病奈瑟菌 (NG) 檢測
  • 梅毒檢測
  • 淋病檢查
  • 單純皰疹病毒（HSV）檢測
  • 人類乳突病毒（HPV）檢測
  • 人類免疫力缺乏病毒（HIV）檢測
  • 滴蟲
  • 脲原體和黴漿菌
  • 其他用途
  • 全球性行為感染傳染病分子診斷市場：依儀器及服務類型細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 分子診斷分析儀
  • 自動聚合酵素鏈鎖反應系統
  • 核酸萃取裝置
  • 診斷服務供應商
  • 維護和校準服務
  • 安裝和培訓服務
  • 全球性行為感染傳染病分子診斷市場：依耗材（類型）細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 去氧核糖核酸萃取套件
  • 核糖核酸萃取試劑套件
  • 聚合酵素鏈鎖反應試劑
  • 核酸探針
  • 標準和參考標準
  • 檢測酵素和緩衝液
  • 全球性行為感染傳染病分子診斷市場：依軟體類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 數據解釋和報告軟體
  • 聚合酵素鏈鎖反應工作流程管理軟體
  • 實驗室資訊管理系統
  • 診斷決策支援軟體
  • 品管監控軟體

第7章 區域和國家分析

  • 全球性行為感染傳染病分子診斷市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球性行為感染傳染病分子診斷市場：按國家/地區、績效和預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 性行為感染傳染病分子診斷市場：競爭格局
  • 性行為感染傳染病分子診斷市場：公司簡介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Hologic Inc.
  • bioMerieux SA
  • QuidelOrtho Corporation
  • QIAGEN NV
  • Cepheid
  • Sansure Biotech Inc.
  • OraSure Technologies Inc.
  • Meridian Bioscience
  • Seegene Inc.
  • Visby Medical Inc.
  • Zeesan Biotech
  • Binx Health Inc.
  • GCC Biotech
  • GeneProof
  • Solone Life Sciences India（P）Ltd.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年性行為感染傳染病分子診斷市場：提供新機會的國家
  • 2029年性行為感染傳染病分子診斷市場：細分領域帶來新機會
  • 2029年性行為感染傳染病分子診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r37822

Molecular diagnostics for sexually transmitted diseases (STDs) involve methods that detect the genetic material, DNA or RNA of infectious agents to confirm the presence of pathogens. These techniques are highly accurate and sensitive, allowing detection even in asymptomatic cases. By analyzing the molecular structure of pathogens, these diagnostics ensure reliable identification, supporting faster and more precise diagnosis.

The primary product categories for molecular diagnostics of STDs include instruments and services, consumables, and software. Instruments comprise the diagnostic devices and platforms used for pathogen detection, while services cover laboratory testing, sample processing, and interpretation of diagnostic results provided by healthcare or diagnostic companies. These diagnostics employ various technologies, including laboratory-based testing and point-of-care testing, and are used in a range of applications such as testing for chlamydia trachomatis (CT), neisseria gonorrhoeae (NG), syphilis, gonorrhea, herpes simplex virus (HSV), human papillomavirus (HPV), human immunodeficiency virus (HIV), trichomonas, ureaplasma, mycoplasma, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The molecular diagnostics for sexually transmitted diseases market research report is one of a series of new reports from The Business Research Company that provides molecular diagnostics for sexually transmitted diseases market statistics, including the molecular diagnostics for sexually transmitted diseases industry global market size, regional shares, competitors with the molecular diagnostics for sexually transmitted diseases market share, detailed molecular diagnostics for sexually transmitted diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the molecular diagnostics for sexually transmitted diseases industry. This molecular diagnostics for sexually transmitted diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The molecular diagnostics for sexually transmitted diseases market size has grown rapidly in recent years. It will grow from $3.31 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth during the historic period can be credited to the rising prevalence of sexually transmitted infections, increased utilization of nucleic acid amplification tests, heightened awareness through government screening initiatives, backing from global health organizations, and early adoption by diagnostic laboratories.

The molecular diagnostics for sexually transmitted diseases market size is expected to see rapid growth in the next few years. It will grow to $5.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be ascribed to an increasing emphasis on early disease detection, rising demand for personalized diagnostics, expansion of sexually transmitted infection surveillance initiatives, growing public-private collaborations, and a greater preference for non-invasive testing approaches. Key trends during this period include advancements in molecular assay technologies, innovations in point-of-care diagnostic devices, development of multiplex PCR-based testing panels, progress in portable and automated systems, and the integration of artificial intelligence for result interpretation.

The rising prevalence of sexually transmitted infections (STIs) is expected to drive growth in the molecular diagnostics for sexually transmitted diseases market. STIs are infections caused by bacteria, viruses, or parasites that are transmitted through sexual contact, affecting the reproductive and urinary systems. The increasing prevalence is largely attributed to inconsistent use of protection methods, which facilitates transmission among sexually active individuals. Molecular diagnostics enable early and accurate detection of pathogens, including in asymptomatic cases, allowing timely treatment, reducing disease spread, and improving patient outcomes. For example, according to the National Association of County and City Health Officials (NACCHO), a US-based nonprofit, a total of 3,755 congenital syphilis cases were reported in January 2024, representing a 31% increase between 2021 and 2022. This growing prevalence is therefore propelling the molecular diagnostics for STDs market.

Key companies in this market are focusing on innovations such as rapid point-of-care polymerase chain reaction (PCR) devices to enhance diagnostic speed, accuracy, and accessibility. These portable devices combine sample preparation, amplification, and detection in a single unit, enabling sensitive pathogen detection outside traditional labs. For instance, in March 2025, Visby Medical, a US-based diagnostic technology company, launched the Visby Medical Women's Sexual Health Test. This single-use, handheld PCR device identifies chlamydia, gonorrhea, and trichomoniasis from vaginal samples in 30 minutes without external instrumentation or cold-chain logistics. Authorized for prescription home use, it represents the first FDA-cleared molecular diagnostic test for multiple STIs usable outside clinical settings, reflecting the trend toward decentralized, accessible testing.

In December 2024, OraSure Technologies, a US-based provider of point-of-care and home diagnostic solutions, acquired Sherlock Biosciences. This acquisition expanded OraSure's molecular diagnostics portfolio in sexual health by integrating Sherlock's over-the-counter chlamydia and gonorrhea self-test, which delivers lab-quality results in under 30 minutes using CRISPR- and isothermal amplification-based platforms. Sherlock Biosciences specializes in molecular diagnostics for sexually transmitted infections.

Major players in the molecular diagnostics for sexually transmitted diseases market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Illumina Inc., Hologic Inc., bioMerieux S.A., QuidelOrtho Corporation, QIAGEN N.V., Cepheid, Sansure Biotech Inc., OraSure Technologies Inc., Meridian Bioscience, Seegene Inc., Visby Medical Inc., Zeesan Biotech, Binx Health Inc., GCC Biotech, GeneProof, and Solone Life Sciences India (P) Ltd.

North America was the largest region in the molecular diagnostics for sexually transmitted diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular diagnostics for sexually transmitted diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the molecular diagnostics for sexually transmitted diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The molecular diagnostics for sexually transmitted diseases market consists of revenues earned by entities by providing services such as test development, sample collection, nucleic acid amplification, and point of care diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular diagnostics for sexually transmitted diseases market also includes sales of polymerase chain reaction kits, isothermal nucleic acid amplification kits, clustered regularly interspaced short palindromic repeats-based tests, and instrument-free molecular diagnostic systems. values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Molecular Diagnostics For Sexually Transmitted Diseases Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on molecular diagnostics for sexually transmitted diseases market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for molecular diagnostics for sexually transmitted diseases ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The molecular diagnostics for sexually transmitted diseases market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Instruments And Services; Consumables; Software
  • 2) By Technology: Laboratory Testing; Point-Of-Care Testing
  • 3) By Application: Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing; Syphilis Testing; Gonorrhea Testing; Herpes Simplex Virus (HSV) Testing; Human Papillomavirus (HPV) Testing; Human Immunodeficiency Virus (HIV) Testing; Trichomonas; Ureaplasma And Mycoplasma; Other Applications
  • Subsegment:
  • 1) By Instruments And Services: Molecular Diagnostic Analyzers; Automated Polymerase Chain Reaction Systems; Nucleic Acid Extraction Instruments; Diagnostic Service Providers; Maintenance And Calibration Services; Installation And Training Services
  • 2) By Consumables: Deoxyribonucleic Acid Extraction Kits; Ribonucleic Acid Extraction Kits; Polymerase Chain Reaction Reagents; Nucleic Acid Probes; Control And Reference Standards; Detection Enzymes And Buffers
  • 3) By Software: Data Interpretation And Reporting Software; Polymerase Chain Reaction Workflow Management Software; Laboratory Information Management Systems; Diagnostic Decision Support Software; Quality Control Monitoring Software
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Illumina Inc.; Hologic Inc.; bioMerieux S.A.; QuidelOrtho Corporation; QIAGEN N.V.; Cepheid; Sansure Biotech Inc.; OraSure Technologies Inc.; Meridian Bioscience; Seegene Inc.; Visby Medical Inc.; Zeesan Biotech; Binx Health Inc.; GCC Biotech; GeneProof; Solone Life Sciences India (P) Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Molecular Diagnostics For Sexually Transmitted Diseases Market Characteristics

3. Molecular Diagnostics For Sexually Transmitted Diseases Market Trends And Strategies

4. Molecular Diagnostics For Sexually Transmitted Diseases Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Molecular Diagnostics For Sexually Transmitted Diseases Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Molecular Diagnostics For Sexually Transmitted Diseases PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Growth Rate Analysis
  • 5.4. Global Molecular Diagnostics For Sexually Transmitted Diseases Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Molecular Diagnostics For Sexually Transmitted Diseases Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Molecular Diagnostics For Sexually Transmitted Diseases Total Addressable Market (TAM)

6. Molecular Diagnostics For Sexually Transmitted Diseases Market Segmentation

  • 6.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instruments And Services
  • Consumables
  • Software
  • 6.2. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Testing
  • Point-Of-Care Testing
  • 6.3. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chlamydia Trachomatis (CT) Or Neisseria Gonorrhoeae (NG) Testing
  • Syphilis Testing
  • Gonorrhea Testing
  • Herpes Simplex Virus (HSV) Testing
  • Human Papillomavirus (HPV) Testing
  • Human Immunodeficiency Virus (HIV) Testing
  • Trichomonas
  • Ureaplasma And Mycoplasma
  • Other Applications
  • 6.4. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Instruments And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Molecular Diagnostic Analyzers
  • Automated Polymerase Chain Reaction Systems
  • Nucleic Acid Extraction Instruments
  • Diagnostic Service Providers
  • Maintenance And Calibration Services
  • Installation And Training Services
  • 6.5. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Deoxyribonucleic Acid Extraction Kits
  • Ribonucleic Acid Extraction Kits
  • Polymerase Chain Reaction Reagents
  • Nucleic Acid Probes
  • Control And Reference Standards
  • Detection Enzymes And Buffers
  • 6.6. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Sub-Segmentation Of Softwares, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Interpretation And Reporting Software
  • Polymerase Chain Reaction Workflow Management Software
  • Laboratory Information Management Systems
  • Diagnostic Decision Support Software
  • Quality Control Monitoring Software

7. Molecular Diagnostics For Sexually Transmitted Diseases Market Regional And Country Analysis

  • 7.1. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Molecular Diagnostics For Sexually Transmitted Diseases Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 8.1. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 9.1. China Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 9.2. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 10.1. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 11.1. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 11.2. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 12.1. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 13.1. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 14.1. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 14.2. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 15.1. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 15.2. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 16.1. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 17.1. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 18.1. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 19.1. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 20.1. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 21.1. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 21.2. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 22.1. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 23.1. North America Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 23.2. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 24.1. USA Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 24.2. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 25.1. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 25.2. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 26.1. South America Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 26.2. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 27.1. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 28.1. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 28.2. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market

  • 29.1. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market Overview
  • 29.2. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Molecular Diagnostics For Sexually Transmitted Diseases Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Landscape And Company Profiles

  • 30.1. Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Landscape
  • 30.2. Molecular Diagnostics For Sexually Transmitted Diseases Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Molecular Diagnostics For Sexually Transmitted Diseases Market Other Major And Innovative Companies

  • 31.1. Hologic Inc.
  • 31.2. bioMerieux S.A.
  • 31.3. QuidelOrtho Corporation
  • 31.4. QIAGEN N.V.
  • 31.5. Cepheid
  • 31.6. Sansure Biotech Inc.
  • 31.7. OraSure Technologies Inc.
  • 31.8. Meridian Bioscience
  • 31.9. Seegene Inc.
  • 31.10. Visby Medical Inc.
  • 31.11. Zeesan Biotech
  • 31.12. Binx Health Inc.
  • 31.13. GCC Biotech
  • 31.14. GeneProof
  • 31.15. Solone Life Sciences India (P) Ltd.

32. Global Molecular Diagnostics For Sexually Transmitted Diseases Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Molecular Diagnostics For Sexually Transmitted Diseases Market

34. Recent Developments In The Molecular Diagnostics For Sexually Transmitted Diseases Market

35. Molecular Diagnostics For Sexually Transmitted Diseases Market High Potential Countries, Segments and Strategies

  • 35.1 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Molecular Diagnostics For Sexually Transmitted Diseases Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer